The use of the peptide lipocalin receptor (ADIPOR) agonist ADP355 in subcutaneous LNCaP xenograft mice slowed tumor growth and retarded the progression of the serum PCa biomarker PSA 124. This evidence concerns the gene KLK3 and posterior cortical atrophy.